Trial Profile
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Olaparib (Primary) ; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROpel
- Sponsors AstraZeneca; AstraZeneca AB
- 02 Feb 2024 Planned End Date changed from 2 Nov 2024 to 28 Apr 2026.
- 27 Jan 2024 Results of gene-by-gene efficacy of O + A vs P + A for pts from PROpel with a HRRm, presented at the 2024 Genitourinary Cancers Symposium
- 12 Jan 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.